8-K: Milestone Pharma Launches CARDAMYST for PSVT in U.S.

Milestone Pharmaceuticals announces the U.S. availability of CARDAMYST (etripamil) nasal spray, the first and only FDA-approved self-administered treatment for adults with paroxysmal supraventricular tachycardia (PSVT).

Summary

• CARDAMYST (etripamil) nasal spray is now available through U.S. retail pharmacies for the management of paroxysmal supraventricular tachycardia (PSVT) in adults.
• It is the first and only FDA-approved self-administered treatment for acute symptomatic episodes of PSVT.
• A national sales force will be deployed in mid-February 2026 to support the promotional launch.
• A comprehensive patient assistance program is in place, offering benefits verification, reimbursement support, and an expected $25 copay cap for eligible commercially insured patients.
• The U.S. Food and Drug Administration (FDA) approved CARDAMYST on December 12, 2025, marking the first FDA approval of a treatment for PSVT in over 30 years.
• An estimated two million people in the United States are currently diagnosed with PSVT.

Sentiment

Score: 8

Explanation: The announcement of the commercial availability of the first and only FDA-approved self-administered treatment for a condition with a significant patient population, after over 30 years without new approvals, is a highly positive development. The establishment of a sales force and patient assistance program further supports a strong commercial outlook, despite ongoing insurer negotiations.

Positives

• CARDAMYST is the first and only FDA-approved self-administered treatment for PSVT in adults, addressing a significant unmet medical need.
• The product is now conveniently available to patients through U.S. retail pharmacies.
• A national sales force is being deployed in mid-February 2026 to support the commercial launch.
• A comprehensive patient assistance program, including an expected $25 copay cap for eligible commercially insured patients, aims to reduce financial and administrative barriers to treatment.
• The FDA approval on December 12, 2025, was the first for PSVT in over 30 years, highlighting the novelty and importance of this therapeutic option.
• CARDAMYST offers patients a convenient, on-demand care option, providing greater control over their condition.

Risks

• Uncertainties related to the timing of initiation, enrollment, completion, evaluation, and results of Milestone's clinical trials.
• Risks and uncertainty related to the complexity inherent in cleaning, verifying, and analyzing trial data.
• Whether clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications.
• General economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international tariffs, Russian hostilities in Ukraine, and ongoing disputes in the Middle East.
• Overall fluctuations in the financial markets in the United States and abroad.
• Risks related to pandemics and public health emergencies.
• Risks related to the sufficiency of Milestone's capital resources and its ability to raise additional capital in the current economic climate.
• Whether Milestone's future interactions with the European Medicines Agency (EMA) will have satisfactory outcomes.
• Whether and when, if at all, Milestone's Marketing Authorization Application (MMA) for etripamil will be approved by the EMA.

Future Outlook

Milestone Pharmaceuticals expects to deploy a national sales force in mid-February 2026 for the promotional launch of CARDAMYST and continues to engage insurers with the goal of achieving wide coverage and affordability for the product. The company is also developing etripamil for PSVT in pediatric patients (Phase 2) and for acute treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR) in adults (Phase 3).

Management Comments

• "Many patients have been waiting for help to take greater control of their PSVT condition. Now that CARDAMYST is available, patients have access to a convenient, self-administered option designed to treat episodes of PSVT wherever and whenever they occur." Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals.
• "Beyond availability, our team continues to engage insurers with the goal of having CARDAMYST widely covered and affordable." Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals.

Industry Context

The launch of CARDAMYST represents a significant advancement in the treatment of paroxysmal supraventricular tachycardia (PSVT), a condition affecting an estimated two million people in the U.S. It is the first FDA-approved treatment for PSVT in over 30 years and the only self-administered option, addressing a long-standing unmet need where healthcare providers have expressed dissatisfaction with existing limited and often burdensome treatment options like emergency department visits or invasive cardiac ablation procedures.

Comparison to Industry Standards

• CARDAMYST is the first FDA-approved treatment for PSVT in over 30 years, indicating a significant gap in new therapeutic options within the industry.
• It is the first and only self-administered treatment for PSVT, offering a novel approach compared to traditional methods that often require emergency department visits or invasive procedures like cardiac ablation.
• The current market for PSVT treatments has left many healthcare providers dissatisfied due to a lack of effective and convenient options, positioning CARDAMYST as a potential market leader in patient-centric care.

Stakeholder Impact

• Shareholders: Positive impact due to the commercial launch of the company's first FDA-approved product, potentially leading to revenue generation and increased market value.
• Patients (PSVT): Highly positive impact by providing a convenient, self-administered, rapid-response treatment option, offering greater control over their condition and potentially reducing the need for emergency department visits.
• Healthcare Providers: Positive impact by offering a new, effective treatment option for PSVT, addressing dissatisfaction with current limited choices.
• Insurers: Ongoing negotiations for formulary placement and coverage, indicating potential for new costs but also improved patient outcomes.

Next Steps

• Deployment of a national sales force in mid-February 2026 for promotional launch.
• Continued negotiations with insurers for formulary placement and coverage of CARDAMYST.
• Ongoing Phase 2 development of etripamil for PSVT in pediatric patients.
• Ongoing Phase 3 development of etripamil for acute treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR) in adults.

Key Dates

Recommendation

The commercial launch of CARDAMYST, the first FDA-approved self-administered treatment for PSVT in over 30 years, represents a significant milestone and a substantial market opportunity for Milestone Pharmaceuticals. This product addresses a clear unmet medical need for an estimated two million U.S. patients. The immediate availability through retail pharmacies, coupled with a national sales force deployment and a patient assistance program, indicates a robust commercialization strategy. While insurer negotiations are ongoing, the unique value proposition of CARDAMYST as a convenient, on-demand therapy positions the company for strong revenue growth and market penetration. This event significantly de-risks the company's primary asset and provides a clear path to commercial success, warranting a strong buy recommendation for long-term investors.

Keywords

CARDAMYST, etripamil, PSVT, paroxysmal supraventricular tachycardia, Milestone Pharmaceuticals, FDA approval, nasal spray, cardiovascular medicine, arrhythmia, self-administered treatment